Cancer Pharmacists Group

This position statement was published in the Asia Pacific Journal of Clinical Oncology, 10 March 2023, https://doi.org/10.1111/ajco.13943

The aims were to (a) review the scientific literature on occupational risk, including exposure mechanisms and risk assessment, with regards to handling monoclonal antibodies (mABs) in healthcare settings; and (b) update the recommendations in the Clinical Oncology Society of Australia (COSA) safe handling of monoclonal antibodies in healthcare settings position statement, published in 2013.

Practitioners should follow the 14 recommendations to lower occupational risk when handling mABs. Another Position Statement update should occur in 5–10 years to ensure the currency of recommendations.

DOWNLOAD 

The CNSA Vascular Access Devices: Evidence-Based Clinical Practice Guidelines, 2024 provide recommendations for clinical practice based on current evidence. This knowledge base, alongside your clinical expertise, individual patient preferences, products and their appropriate application, and finally within your local workplace or environment can be integrated together into comprehensive approach to vascular access management for the individual cancer patient.

The ADDIKD guideline was developed by an expert clinician and academic volunteer working group using the GRADE approach of analysing available scientific and clinical evidence and accepted approaches in nephrology, clinical pharmacology, and cancer care. The guideline is targeted at clinicians.